SmartClot: Personalized platform for the combined evaluation of platelet and coagulation factor in haemostasis or during antithrombbotic therapy

Información del proyecto

Smart Clot

Identificador del acuerdo de subvención: 827998

DOI

10.3030/827998

Proyecto cerrado

Fecha de la firma de la CE 2 Agosto 2018

Fecha de inicio 1 Agosto 2018

Fecha de finalización 30 Noviembre 2018

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

SEDICIDODICI SRL
Italy

Periodic Reporting for period 1 - Smart Clot (SmartClot: Personalized platform for the combined evaluation of platelet and coagulation factor in haemostasis or during antithrombbotic therapy)

Período documentado: 2018-08-01 hasta 2018-11-30

Resumen del contexto y de los objetivos generales del proyecto

Cardiovascular diseases (CVDs) are the leading cause of mortality globally, causing 3.9 million deaths annually in EU. However, early identification and control of patients at high risk of suffering CVDs can potentially reduce these figures.
We at SediciDodici have developed an innovative in-vitro diagnostic device called Smart Clot, which can provide a global quantitative assessment of platelet and coagulation function in blood samples within minutes from obtaining patients´ specimen, which can be life-saving in conditions of surgical or medical emergency. Based on the current prototype, which consists on an analysis equipment and a perfusion cartridge mostly used manually, we intend to produce a low-cost and improved version. Thus, the project will be oriented towards obtaining the automation and scale-up of the platform, software development and implementation, and clinical validation.
The FS confirms the uniqueness of our innovation, its technical feasibility and commercial profitability.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Technical FS defines the current prototype (TRL 7), and the improvement to be done, outlines and validates the work plan to scale-up the platform and gain capability for large deployment once we reach the market, and analyses technical risks and their contingency and mitigation measures.
Commercial FS offers an in-depth study on cardiovascular medical device market, evaluates the existing solutions to diagnose CVDs (competitors) and the regulatory and certification framework, conducts a IPR study to confirm our freedom to operate, and defines an exploitation and dissemination plan.
Financial FS makes a production cost assessment of the project (~€2.5 million) and offers a business projections analysis for the first 5-years of commercialization.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Smart Clot will reduce burden of CVDs by improving the medical prevention technology already available. Additionally, it will also have a positive impact for the company´s growth, reaching a ROI of 2.60 by the end of 2024.

smart-clot-img1.png

smart-clot-img2.jpg